Asymptomatic Cardiac Metastases From Esophageal Cancer: A Case Report Of Ante-mortem Detection And Literature Review

Carlo Signorelli, Amedeo Pergolini, Giordano Zampi, Andrea Vallone, Enzo Maria Ruggeri

1. Oncology, Belcolle Hospital, Viterbo, ITA 2. Cardiology, San Camillo-Forlanini Hospital, Rome, ITA 3. Cardiology, Belcolle Hospital, Viterbo, ITA 4. Radiology, San Camillo-Forlanini Hospital, Rome, ITA

Corresponding author: Carlo Signorelli, carlo.signorelli@asl.vt.it

Abstract

Metastatic spread to the heart from neoplasms is very rare, often silent and rarely gains clinical attention. Usually, it correlates with widespread metastatic disease and is suggestive of a poor prognosis. Most cardiac metastases (CM) are detected following post-mortem studies with only a handful reported antemortemly. Here, we report a case of an asymptomatic cardiac metastasis from esophageal carcinoma and review the literature. In late July 2014, a 73-year-old woman diagnosed with locally advanced esophageal squamous cell carcinoma was admitted to our institution. Cardiothoracic metastases were not detected at basal computed tomography (CT) scan. The patient was submitted to concurrent cisplatin and radiotherapy. Just before surgery, a CT scan revealed two metastases in the right ventricle and in the interventricular septum. Transthoracic echocardiography and an endomyocardial biopsy confirmed the diagnosis of squamous cell carcinoma from the esophageal origin. In February 2015, chemotherapy was started, but after two courses of gemcitabine, a pulmonary embolism and then a congestive heart failure caused death of the patient on April 2015. Reviewing the literature, 14 cases with an antemortem diagnosis of CM from esophageal cancer were reported. Our patient should be the fifteenth case with an uncommon presentation without symptoms or signs in the diagnosis. Our case highlights that patients should be evaluated using echocardiography for CM, even if asymptomatic.

Introduction

Cardiac metastases (CM) are very rare, often silent and rarely gain clinical attention. As in the primary tumors, the most frequent symptoms are congestive heart failure, valvular heart disease, pericardial effusion, electrocardiographic changes, dysrhythmia, syncope, embolism, cardiomegaly and it may arise suddenly. However, signs are often overlooked. Usually, it correlates with widespread metastatic disease and is suggestive of a poor prognosis. Although cardiac dissemination of malignant disease is a common finding during an autopsy, it rarely produces clinical symptoms [1]. Most of CM are detected following post-mortem studies with only a handful reported antemortemly. Epidemiological information is predominantly based on autopsy studies with incidences ranging from 2.3%-18.3% of cancer patients and from 0.2%-6.5% in unselected autopsy series [2-3]. Metastatic spread of cancers to the heart is more common than primary cardiac tumors. CM from tumors arising from the esophagus and pericardial effusions caused by metastatic cancer are rare; squamous cell carcinoma causing
these events is extremely uncommon. It may appear during the evolution of this neoplasm and the tumor spread to the heart is usually caused by direct invasion. Not infrequently, cardiac tumor invasion contributes to the mechanism of death. The most of cardiac tumors are metastases mainly from pleural mesothelioma, melanoma, lung adenocarcinoma, undifferentiated carcinomas, lung squamous cell carcinoma, breast carcinoma, ovarian carcinoma, lymphomyeloproliferative neoplasms, bronchioalveolar carcinoma, gastric carcinoma, renal carcinoma, and pancreatic carcinoma and occur more commonly on the right side than the left side of the heart [2]. Only tumors of the central nervous system have not been proven to develop CM. Right ventricular metastases from esophageal cancer are even rare, with few such cases reported in the literature to date, being focused more on imaging findings from cardiac echocardiography [4]. Compared to metastases to the myocardium, direct extension to pericardium or regional lymphatic invasion are a more frequent route for invading the heart [2]. Since most of CM appear in the terminal stage of cancer, the prognosis is grave and therapeutic options are limited to palliative treatment of symptoms and chemotherapy. Here, we report a case of ante-mortem detection of asymptomatic CM from esophageal carcinoma and a review of the literature.

Case Presentation

In July 2014, a 73-year-old woman was diagnosed with locally advanced stenosing squamous cell carcinoma of the middle third of the esophagus (maximum diameter 40 mm) and was admitted to our institution. The patient had been suffering from chronic bronchitis secondary to tobacco consumption. Symptoms referred by the patient included dysphagia, weight loss, and right shoulder blade pain. Routine blood tests, including tumor markers and electrocardiogram (ECG) were normal. A computed tomography (CT) scan showed only the esophageal cancer with regional pathological lymph nodes. No basal evidence of cardiothoracic metastases. Transthoracic echocardiography revealed an ejection fraction of about 60%. The patient was planned to receive primary treatment with two courses of concurrent cisplatin (60 mg/mq) and radiotherapy (50 Gy totally with daily fractionation of 2 Gy). The patient had a clinical benefit. In November, just before undergoing surgery, a CT scan and an endoscopy showed a reduction of both the esophageal mass and lymph-nodes but revealed the presence of two suspected metastases with a maximum diameter of 50 mm, one in the right ventricle and one in the interventricular septum (Figures 1–2).
FIGURE 1: Computed tomography (CT) scan of the heart
Axial plane contrast-enhanced.

FIGURE 2: Computed tomography (CT) scan of the heart
Multi planar reformation contrast-enhanced. Evidence of filling defect within the right ventricular cavity in correspondence with the interventricular septum.

The transthoracic echocardiography (as seen in Figure 3) and a magnetic resonance imaging (MRI) confirmed the two CM occupying the right ventricle near to the outflow tract and adherent to the interventricular septum (Figures 4-7).

FIGURE 3: Transthoracic echocardiography
A. Short-axis, great vessels off-axis view, showing a lobulated, cerebriform mass in the right ventricle near to the outflow tract. B. Short-axis, middle ventricle view, showing a mass occupying the right ventricle, adherent to the interventricular septum, with an anechoic central core. C. Subcostal view, showing a mass, with multiple anechoic foci, occupying a large amount of the right ventricle.

FIGURE 4: Cardiac magnetic resonance imaging (MRI)
FIGURE 5: Cardiac magnetic resonance imaging (MRI)

Four chambers cine MRI.
FIGURE 6: Cardiac magnetic resonance imaging (MRI)

TSE_T1 2 chambers cine MRI targeted for the study of the right ventricle.
An endomyocardial biopsy revealed the diagnosis of squamous cell carcinoma from esophageal origin, p63+, cytokeratin 7 and 20-, CDX2- (Figure 8).
Both surgery and radiotherapy were not indicated as therapeutic options by a multidisciplinary oncology group. As the patient preference was to be treated, in February 2015 chemotherapy with gemcitabine was started, but after two courses a pulmonary embolism and then a congestive heart failure conducted her to death in April.

**Discussion**

The presented case reports an ante-mortem diagnosis of CM from known esophageal cancer. As more of 90% of CM is silent, diagnosis is often difficult and mostly discovered at necropsy. If symptoms or signs are present, they are often overshadowed in the setting of widespread metastatic disease and the patient usually die from other metastatic lesions. Since the introduction of 2D-echocardiography, multislice CT, and MRI, CM have been more frequently diagnosed in vivo. Up until now, only 14 cases with an ante-mortem diagnosis and treatment of intracardiac metastases from esophageal cancer have been described in the literature (Table I).
<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Age</th>
<th>Gender</th>
<th>Treatment</th>
<th>Imaging Studies</th>
<th>Diagnosis</th>
<th>Symptoms</th>
<th>Additional Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Youn et al.</td>
<td>2002</td>
<td>65</td>
<td>M</td>
<td>SCC</td>
<td>eRT, simultaneous Echocardiogram, MRI, coronary angiography</td>
<td>Endocardium RV, Heart murmur, Endomyocardial biopsy</td>
<td>Heart murmur, eRT</td>
<td></td>
</tr>
<tr>
<td>Tayama et al.</td>
<td>2011</td>
<td>48</td>
<td>M</td>
<td>SCC</td>
<td>none, simultaneous echocardiogram</td>
<td>Epicardium RV, Cardiac tamponade, dyspnea</td>
<td>Open excision, BSC Rapid clinical deterioration</td>
<td>1M 1M</td>
</tr>
<tr>
<td>Cheng et al.</td>
<td>2013</td>
<td>58</td>
<td>M</td>
<td>SCC</td>
<td>CCRT Surgery, Chest CT scan</td>
<td>Myocardium LV, Dyspnea, Chest tightness mimicking myocardial infarction</td>
<td>* CTx</td>
<td></td>
</tr>
<tr>
<td>Consoli et al.</td>
<td>2011</td>
<td>67</td>
<td>M</td>
<td>SCC</td>
<td>CCRT MRI, 11M Echocardiogram, MRI</td>
<td>Endocardium, pericardial effusion LV, RV</td>
<td>Dyspnea, palpitations, cardiac arrhythmia, hypotension</td>
<td>CTx Neoplastic effusion 6M 16M</td>
</tr>
<tr>
<td>Oliveira et al.</td>
<td>2012</td>
<td>81</td>
<td>M</td>
<td>SCC</td>
<td>Surgery, 9M Echocardiogram, CT scan</td>
<td>Myocardium pericardial RV, Acute stroke</td>
<td>CT-guided needle aspiration biopsy pneumonia 1M 10M</td>
<td></td>
</tr>
<tr>
<td>Basaran et al.</td>
<td>2013</td>
<td>80</td>
<td>F</td>
<td>SCC</td>
<td>Surgery, 12M echocardiogram</td>
<td>Myocardium LA, LV, Ventricular tachycardia</td>
<td>* BSC RHF 0M 12M</td>
<td></td>
</tr>
<tr>
<td>Maeda et al.</td>
<td>2009</td>
<td>62</td>
<td>F</td>
<td>SCC</td>
<td>Surgery, 6M CT scan echocardiogram</td>
<td>Myocardium LV, none, * CTx cancer</td>
<td>CTx cancer &quot; &quot;</td>
<td></td>
</tr>
<tr>
<td>Moulin-Romsee et al.</td>
<td>2007</td>
<td>47</td>
<td>F</td>
<td>SCC</td>
<td>CCRT Surgery, FDG-PET/TC RA</td>
<td>Myocardium RV, Chest pain, * eRT pneumonia</td>
<td>2M 13M</td>
<td></td>
</tr>
<tr>
<td>Al-Mamgani et al.</td>
<td>2007</td>
<td>60</td>
<td>M</td>
<td>SCC</td>
<td>CCRT MRI, 11M CT scan ecocardiography</td>
<td>Myocardium RV, Chest pain, * eRT pneumonia</td>
<td>2M 13M</td>
<td></td>
</tr>
<tr>
<td>Nakamura et al.</td>
<td>2005</td>
<td>53</td>
<td>F</td>
<td>SCC</td>
<td>* simultaneous CT scan ecocardiography</td>
<td>* Ball tumor in RA, Cardiac murmur, Dyspnea on effort</td>
<td>Open excision CCRT Surgery cancer 5M 5M</td>
<td></td>
</tr>
<tr>
<td>Chelko et al.</td>
<td>1993</td>
<td>75</td>
<td>M</td>
<td>melanoma</td>
<td>Medical therapy, simultaneous CT scan ecocardiography LA</td>
<td>CT scan ecocardiography, Dysphagia Weight loss Pericardial effusion experimental protocol with 99mTc labelled antimelanoma monoclonal Ab</td>
<td>Dysphagia 5MTC labelled, BSC &quot; &quot;</td>
<td></td>
</tr>
<tr>
<td>Abbate et al.</td>
<td>2015</td>
<td>49</td>
<td>F</td>
<td>SCC</td>
<td>CTX CCRT MRI, 20M CT scan MRI LV</td>
<td>none surgical debulking CTx ischemic stroke</td>
<td>12M 44M</td>
<td></td>
</tr>
</tbody>
</table>
The majority of these cases were not single metastases. Main characteristics of these cases were: median age 59.9 years (the incidence of CM reported from autopsies is variable ranging from 2.3% to 18.3%, predominantly in the sixth and seventh decade of life); prevalence of male (57.1%) (although the frequency of primary tumours was found to be different for men and women, 46% in men and 31.7% in women, no differences were detected in the incidence of CM from post-mortem examinations); the predominant histologic type was squamous cell carcinoma (92.3%); median time to the onset of this kind of metastases: 8.9 months; the method of choice to detect recurrence was echocardiography in 78.5% of cases; the right side of the heart was involved in the same way as the left (50%); the structure primarily affected was myocardium (70%) (unlike the cases diagnosed post-mortem in which the most common site was the epicardium); the main treatment with palliative purposes was surgery (36.3%), followed by concurrent chemo-radiation, chemo-radiation before surgery (18.1%), best supportive care, radiotherapy and chemotherapy followed by concurrent chemo-radiotherapy before surgery (9%); the median time to death from Cardiac metastases was 5.3 months with an overall survival of approximately 18.2 months. Survival is determined by the inherent aggressiveness of the cancer manifested by tumor size, grade and distant metastasis at presentation. To date, our patient is the fifteenth case in the literature, with an uncommon presentation without symptoms or signs with a median time to death from cardiac recurrence and an overall survival respectively of six and 10 months.

A variety of diagnostic imaging and hemodynamic techniques have been applied in the diagnostic process of all cases published, including echocardiography, CT, MRI, and even right heart catheterization. The method of choice to detect CM was two-dimensional echocardiography, the non-invasive imaging technique enabling clarification of the location, size, shape, number and mobility of the masses but it is usually limited in tissue characterization. Transesophageal echocardiography can give more information than the approach transthoracic and in the case of patients with specific physical habits, overcomes the disadvantage of poor acoustic window. However, echocardiography is usually limited in tissue characterization. Definite diagnosis requires pathological examination of tumor tissue. Electrocardiography is not specific. Localized and prolonged ST-segment elevation without Q waves appears to be pathognomonic for myocardial tumor invasion. Cardiac MRI could be the diagnostic tool of choice in the assessment of patients with esophageal cancer when CM are suspected; it offers improved resolution, a larger field of view and superior soft-tissue contrast, it is not invasive and does not require ionizing radiation or exposure to nephrotoxic contrast agents. Although there is overlap of the MRI characteristics of several cardiac masses, MRI is a

<table>
<thead>
<tr>
<th>Trocino 2015</th>
<th>48</th>
<th>F</th>
<th>SCC</th>
<th>Surgery</th>
<th>36M</th>
<th>CT scan</th>
<th>Echocardiography</th>
<th>Myocardium LV</th>
<th>none</th>
<th>myocardial biopsy</th>
<th>CTx</th>
<th>massive cardioembolic cerebral stroke</th>
<th>10M</th>
<th>48M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Our case 2019</td>
<td>73</td>
<td>F</td>
<td>SCC</td>
<td>CCRT</td>
<td>5M</td>
<td>Echocardiography, MRI, CT scan, coronary angiography</td>
<td>Endomyocardium RV</td>
<td>none</td>
<td>Endomyocardial biopsy</td>
<td>CTx</td>
<td>RHF</td>
<td>6M</td>
<td>10M</td>
<td></td>
</tr>
</tbody>
</table>

*no available data; CCRT, concurrent chemoradiotherapy; CT, computed tomography; CTx, chemotherapy; eRT, external radiotherapy; M, months; MRI, magnetic resonance imaging; RHF, right heart failure; SCC, squamous cell carcinoma; Tx, therapy.

**TABLE 1: Literature review of cardiac metastases from esophageal cancer with an ante-mortem diagnosis**
reliable tool to identify necrosis, extra-cardiac spread, pericardial effusion and to exclude lipomas, fibromas and hemangiomas as well as thrombus or lipomatous hypertrophy. However, its inability to evaluate calcification constitutes an important limitation of MRI. Multidetector computed tomography is useful for the evaluation of calcification and fat content of a cardiac mass [19]. In descending order of frequency, epicardium (75.5%), followed by myocardium (38.2%) and endocardium (15.5%) are involved [20]. In our patient, hematogenous spread was a possible route for cardiac involvement, since the tumor was located on the ventricular septum and protruded into the right ventricular cavity. CM are usually bilateral, small and multiple; however, single large lesions are also observed. Valvular metastatic deposits, intracavitary or endocardial such as the one described in our case, occur in less than 6% of cases. Tachyarrhythmia is found often in these patients and may lead to syncope. Coronary occlusion or compression from tumor masses can lead to myocardial infarction, heart failure, and death. A typical clinical pattern of cardiac disease progression is characterized by a worsening performance status, exacerbation of cardiac symptoms, including tamponade, arrhythmia, obstruction, or dilated cardiomyopathy, representing one of the terminal events as in the case of the reported patient. CM are usually diagnosed in the setting of generalized carcinomatosis. At this stage, treatment must be with palliative intention to improve the quality of life, while in rare cases with a long life expectancy and a good performance status, when the heart is the only site of metastasis, it could be with curative intent.

Current treatment options do little to encourage a positive outlook and are particularly limited in cases of CM. Because cardiac tissue involvement is frequently diffuse, the usefulness of chemotherapy or surgery is questionable. Chemotherapy is recommended in chemosensitive primary tumors. Surgery is the treatment of choice in highly selected patients with a long life expectancy and a good performance status and it is only indicated in exceptional cases of solitary intracavitary heart metastases leading to obliteration of the cardiac chambers or valve obstruction. Surgery offers the best chance of prolonged survival. Because patients suitable for surgery generally have a better prognosis than inoperable patients, postoperative chemotherapy and/or radiotherapy should be given to reduce the chance of local recurrence. In such patients, it is important to keep the treatment time as short as possible. Radiotherapy should be attempted to relieve symptoms, to produce local control, and to stabilize hemodynamic disturbances. Short-course radiotherapy may be suitable to achieve these objectives. Radiotherapy may lead to fibrosis of the lung or of the myocardium, and thus to disorders of the conduction system and also to pericarditis. Whatever the treatment selected, the clinical evolution is disappointing, and patients with heart metastases die within a year of the diagnosis. This poor prognosis makes it important to define the most appropriate therapeutic strategy may be taking the approach to surgery in cases where the latter is possible.

Conclusions

CM are unfavorable prognostic factors of survival and therapies are mostly palliative in order to ameliorate symptoms since cardiac dissemination mostly occurs in the setting of widespread metastatic disease. The therapeutic efficacy of an antineoplastic treatment must be balanced with its side effects and quality of life. The decision should involve a multi-disciplinary team. As heart metastases are often incurable, surgery is not an optimal option but in some patients can be useful for the relief of symptoms. Systemic chemotherapy is usually the most beneficial treatment. In patients who have known metastatic neoplasms and who present with cardiac manifestations, the clinician should be alert to the possibility of CM. However, treatment of all the metastatic cardiac tumors provides only palliation. Echocardiography performed...
periodically in patients with esophageal carcinoma could permit recognition of CM before the occurrence of overt cardiac signs leading to a chance for an aggressive surgical therapy. Accumulation of reports about treating cases of CM may help to clarify the natural course of this kind of lesions and how to treat them. After our review, we suggest that patients with a high risk of recurrence should be carefully evaluated using echocardiography for CM, even without symptoms. With the advent of modern diagnostic tools, better chemotherapy regimens, and better radiation techniques, and with the implementation of better perioperative care, patients with cancer have a somewhat improved survival. With increased longevity, a trend of increased incidence of CM has been shown in different studies. Because of the aforementioned factors, together with the widespread use of modern imaging techniques, an increase in the frequency of the ante-mortem diagnosis of heart metastases is to be expected in the near future.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

Many thanks to Prof. Lucia Rosalba Grillo, Department of Pathology - S.Camillo-Forlanini Hospital - Rome, for performing histological analysis.

References


